New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial

Clin Res Cardiol. 2021 Feb;110(2):153-161. doi: 10.1007/s00392-020-01695-w. Epub 2020 Jul 30.

Abstract

Introduction: Current health care data reveal suboptimal prevention in patients with coronary artery disease and an unmet need to develop effective preventive strategies. The New Technologies for Intensive Prevention Programs (NET-IPP) Trial will investigate if a long-term web-based prevention program after myocardial infarction (MI) will reduce clinical events and risk factors. In a genetic sub study the impact of disclosure of genetic risk using polygenic risk scores (PRS) will be assessed.

Study design: Patients hospitalized for MI will be prospectively enrolled and assigned to either a 12-months web-based intensive prevention program or standard care. The web-based program will include telemetric transmission of risk factor data, e-learning and electronic contacts between a prevention assistant and the patients. The combined primary study endpoint will comprise severe adverse cardiovascular events after 2 years. Secondary endpoints will be risk factor control, adherence to medication and quality of life. In a genetic sub study genetic risk will be assessed in all patients of the web-based intensive prevention program group by PRS and patients will be randomly assigned to genetic risk disclosure vs. no disclosure. The study question will be if disclosure of genetic risk has an impact on patient motivation and cardiovascular risk factor control.

Conclusions: The randomized multicenter NET-IPP study will evaluate for the first time the effects of a long-term web-based prevention program after MI on clinical events and risk factor control. In a genetic sub study the impact of disclosure of genetic risk using PRS will be investigated.

Keywords: Disclosure of genetic risk; Myocardial infarction; Polygenic risk scores; Web-based prevention program.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / prevention & control*
  • Prospective Studies
  • Quality of Life
  • Risk Factors
  • Secondary Prevention / methods*
  • Telemetry / methods*